The order of vasopressor discontinuation and incidence of hypotension: a retrospective cohort analysis

Xuan Song, Xinyan Liu, Kimberly D Evans, Ryan D Frank, Erin F Barreto, Yue Dong, Chang Liu, Xiaolan Gao, Chunting Wang, Kianoush B Kashani, Xuan Song, Xinyan Liu, Kimberly D Evans, Ryan D Frank, Erin F Barreto, Yue Dong, Chang Liu, Xiaolan Gao, Chunting Wang, Kianoush B Kashani

Abstract

The optimal order of vasopressor discontinuation during shock resolution remains unclear. We evaluated the incidence of hypotension in patients receiving concomitant vasopressin (VP) and norepinephrine (NE) based on the order of their discontinuation. In this retrospective cohort study, consecutive patients receiving concomitant VP and NE infusions for shock admitted to intensive care units were evaluated. The primary outcome was hypotension incidence following discontinuation of VP or NE (VP1 and NE1 groups, respectively). Secondary outcomes included the incidence of acute kidney injury (AKI) and arrhythmias. Subgroup analysis was conducted by examining outcomes based on the type of shock. Of the 2,035 included patients, 952 (46.8%) were VP1 and 1,083 (53.2%) were NE1. VP1 had a higher incidence of hypotension than NE1 (42.1% vs. 14.2%; P < 0.001), longer time to shock reversal (median: 2.5 vs. 2.2 days; P = .009), higher hospital [29% (278/952) vs. 24% (258/1083); P = .006], and 28-day mortality [37% (348/952) vs. 29% (317/1,083); P < 0.001] when compared with the NE1 group. There were no differences in ICU mortality, ICU and hospital length of stay, new-onset arrhythmia, or AKI incidence between the two groups. In subgroup analyses based on different types of shock, similar outcomes were observed. After adjustments, hypotension in the following 24 h and 28-day mortality were significantly higher in VP1 (Odds ratios (OR) 4.08(3.28, 5.07); p-value < .001 and 1.27(1.04, 1.55); p-value < .001, respectively). Besides, in a multivariable model, the need for renal replacement therapy (OR 1.68 (1.34, 2.12); p-value < .001) was significantly higher in VP1. Among patients with shock who received concomitant VP and NE, the VP1 group was associated with a higher incidence of hypotension in comparison with NE1. Future studies need to validate our findings and their impact on clinical outcomes.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Figure 1
Figure 1
Study flow chart of patient enrollment.
Figure 2
Figure 2
Cumulative incidence of hypotension following first vasopressor discontinuation by order of vasopressor discontinued.
Figure 3
Figure 3
Cumulative incidence of shock reversal following first vasopressor discontinuation by order of vasopressor discontinued.

References

    1. Marchick MR, Kline JA, Jones AE. The significance of non-sustained hypotension in emergency department patients with sepsis. Intensive Care Med. 2009;35:1261–1264. doi: 10.1007/s00134-009-1448-x.
    1. Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki LM, Pettila V. Hemodynamic variables related to outcome in septic shock. Intensive Care Med. 2005;31:1066–1071. doi: 10.1007/s00134-005-2688-z.
    1. Gutierrez G, Reines HD, Wulf-Gutierrez ME. Clinical review: Hemorrhagic shock. Crit. Care. 2004;8:373–381. doi: 10.1186/cc2851.
    1. Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Crit. Care Med. 2018;46:997–1000. doi: 10.1097/ccm.0000000000003119.
    1. van Diepen S, et al. Contemporary management of cardiogenic shock: A scientific statement from the American Heart Association. Circulation. 2017;136:e232–e268. doi: 10.1161/CIR.0000000000000525.
    1. Park SK, et al. The effect of early goal-directed therapy for treatment of severe sepsis or septic shock: A systemic review and meta-analysis. J. Crit. Care. 2017;38:115–122. doi: 10.1016/j.jcrc.2016.10.019.
    1. Russell JA. Vasopressor therapy in critically ill patients with shock. Intensive Care Med. 2019;45:1503–1517. doi: 10.1007/s00134-019-05801-z.
    1. Thongprayoon C, et al. Temporal trends in the utilization of vasopressors in intensive care units: An epidemiologic study. BMC Pharmacol. Toxicol. 2016;17:19. doi: 10.1186/s40360-016-0063-z.
    1. Rhodes A, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377. doi: 10.1007/s00134-017-4683-6.
    1. Merouani M, et al. Norepinephrine weaning in septic shock patients by closed loop control based on fuzzy logic. Crit. Care. 2008;12:R155. doi: 10.1186/cc7149.
    1. Bauer SR, et al. Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: A retrospective cohort study. J. Crit. Care. 2010;25(362):e367–e362. doi: 10.1016/j.jcrc.2009.10.005.
    1. Sacha GL, et al. Hypotension Risk based on vasoactive agent discontinuation order in patients in the recovery phase of septic shock. Pharmacotherapy. 2018;38:319–326. doi: 10.1002/phar.2082.
    1. Vincent JL, De Backer D. Circulatory shock. N. Engl. J. Med. 2013;369:1726–1734. doi: 10.1056/NEJMra1208943.
    1. Vincent JL, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/bf01709751.
    1. Singer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287.
    1. Lier H, Bernhard M, Hossfeld B. Hypovolemic and hemorrhagic shock. Anaesthesist. 2018;67:225–244. doi: 10.1007/s00101-018-0411-z.
    1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron. Clin. Pract. 2012;120:c179–184. doi: 10.1159/000339789.
    1. Upton GJ. Fisher's exact test. J. R. Stat. Soc. A. Stat. Soc. 1992;155:395–402. doi: 10.2307/2982890.
    1. Russell JA, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N. Engl. J. Med. 2008;358:877–887. doi: 10.1056/NEJMoa067373.
    1. Hammond DA, et al. Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock. J. Intensive Care Med. 2019;34:805–810. doi: 10.1177/0885066617714209.
    1. Bissell BD, Magee C, Moran P, Bastin MLT, Flannery AH. Hemodynamic instability secondary to vasopressin withdrawal in septic shock. J. Intensive Care Med. 2019;34:761–765. doi: 10.1177/0885066617716396.
    1. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989–1002. doi: 10.1378/chest.120.3.989.
    1. Rozenfeld V, Cheng JW. The role of vasopressin in the treatment of vasodilation in shock states. Ann. Pharmacother. 2000;34:250–254. doi: 10.1345/aph.19066.
    1. Morales D, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation. 1999;100:226–229. doi: 10.1161/01.cir.100.3.226.
    1. Barrett LK, Singer M, Clapp LH. Vasopressin: Mechanisms of action on the vasculature in health and in septic shock. Crit. Care Med. 2007;35:33–40. doi: 10.1097/.
    1. Landry DW, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122–1125. doi: 10.1161/01.cir.95.5.1122.
    1. Russell JA, et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am. J. Respir. Crit. Care Med. 2013;188:356–364. doi: 10.1164/rccm.201302-0355OC.
    1. Barrett LK, et al. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit. Care Med. 2007;35:2337–2343. doi: 10.1097/01.ccm.0000281861.72907.17.
    1. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin. Neurosci. 2006;8:383–395. doi: 10.31887/DCNS.2006.8.4/ssmith.
    1. Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: Adverse effects of adrenergic stress. J. Intensive Care Med. 2009;24:293–316. doi: 10.1177/0885066609340519.
    1. Schmittinger CA, et al. Adverse cardiac events during catecholamine vasopressor therapy: A prospective observational study. Intensive Care Med. 2012;38:950–958. doi: 10.1007/s00134-012-2531-2.
    1. Dunser MW, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med. 2002;28:746–751. doi: 10.1007/s00134-002-1265-y.
    1. Hajjar LA, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial. Anesthesiology. 2017;126:85–93. doi: 10.1097/ALN.0000000000001434.
    1. Hajjar LA, et al. Vasopressin versus norepinephrine for the management of septic shock in cancer patients: The VANCS II randomized clinical trial. Crit. Care Med. 2019;47:1743–1750. doi: 10.1097/CCM.0000000000004023.
    1. Gordon AC, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial. JAMA. 2016;316:509–518. doi: 10.1001/jama.2016.10485.
    1. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med. 2006;32:1782–1789. doi: 10.1007/s00134-006-0378-0.
    1. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576–582. doi: 10.1097/00000542-200203000-00011.
    1. Russell JA, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit. Care Med. 2009;37:811–818. doi: 10.1097/CCM.0b013e3181961ace.
    1. Gordon AC, et al. The interaction of vasopressin and corticosteroids in septic shock: A pilot randomized controlled trial. Crit. Care Med. 2014;42:1325–1333. doi: 10.1097/ccm.0000000000000212.
    1. O'Callaghan DJ, Gordon AC. What's new in vasopressin? Intensive Care Med. 2015;41:2177–2179. doi: 10.1007/s00134-015-3849-3.
    1. Ertmer C, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock. 2007;27:281–288. doi: 10.1097/01.shk.0000235140.97903.90.
    1. Schurr JW, Szumita PM, DeGrado JR. Neuroendocrine derangements in early septic shock: Pharmacotherapy for relative adrenal and vasopressin insufficiency. Shock. 2017;48:284–293. doi: 10.1097/SHK.0000000000000864.
    1. Bredhold BE, et al. Impact of the sequence of norepinephrine and vasopressin discontinuation in patients recovering from septic shock. Hosp. Pharm. 2020;55:26–31. doi: 10.1177/0018578718817469.
    1. Hammond DA, et al. Effects of norepinephrine and vasopressin discontinuation order in the recovery phase of septic shock: A systematic review and individual patient data meta-analysis. Pharmacotherapy. 2019;39:544–552. doi: 10.1002/phar.2265.
    1. Saito T, et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: Hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med. 1995;21:204–210. doi: 10.1007/BF01701473.
    1. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004;30:1276–1291. doi: 10.1007/s00134-004-2283-8.
    1. Hammond DA, et al. Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies. J. Am. Coll. Clin. Pharmacy. 2019;2:257–267. doi: 10.1002/jac5.1079.
    1. Lam SW, et al. Cost-effectiveness of second-line vasopressors for the treatment of septic shock. J. Crit. Care. 2020;55:48–55. doi: 10.1016/j.jcrc.2019.10.005.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅